New Delhi: Drug firm Suven Life Sciences Ltd on Monday said it has received three product patents for CNS molecules, two from Eurasia and one from Canada, which could be used for treating various central nervous system disorders. The product patents are valid through 2027, Suven Life Sciences said in a filing to BSE.
The company has received approval for molecules that could be used in the treatment of neurodegenerative disorders like Parkinson’s, Alzheimer’s and Schizophrenia, it added. Products developed out of these molecules may be out-licensed at various phases of clinical development like Phase I or Phase II, the company said.
Commenting on the development, Suven CEO Venkat Jasti said: “We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally.”
With these new patents, the company now has a total of 10 patents from Canada and 12 patents from Eurasia, the company said. Shares of Suven Life Sciences ended up 1.32% at Rs 30.80 on BSE on Monday.